Michael Thirman is an Oncology physician affiliated with University of Illinois Chicago. OpenAlex indexes 223 publications with 10,868 citations (h-index 47); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5841 S Maryland Ave
Chicago, IL 606371443
Telephone
888-824-0200Registry record last updated 24 Oct 2022.
Clinical trials
- Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL
Sponsor: University of Chicago
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Syndax Pharmaceuticals, Inc.Program year202518 payments$13,772openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- ABBVIE INC.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
45.4%Kinase inhibitor26.9%Imbruvica57%Calquence22%Jaypirca21%Part D<11 patientsBCL-2 Inhibitor18.5%Venclexta100%Part D<11 patientsDermatology
18.1%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor18.1%Acyclovir100%Part D<11 patientsAnti-infectives
17.1%Short-acting sulfonamides11.6%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsAzole Antifungal5.6%Fluconazole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 1999–2021 per NIH RePORTER. The latest:
- Instructive role of MLL fusion proteins in lineage determination and leukemogenesis
University of Chicago
FY2021$594,545R01CA215504 - Instructive role of MLL fusion proteins in lineage determination and leukemogenesis
University of Chicago
FY2020$594,545R01CA215504 - Instructive role of MLL fusion proteins in lineage determination and leukemogenesis
University of Chicago
FY2019$576,709R01CA215504
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Long‐term follow‐up of <scp>VIALE‐A</scp>: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia
American Journal of Hematology
2024 - Menin Inhibition With Revumenib for <i>KMT2A</i> -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)
Journal of Clinical Oncology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Jerry Krishnan, MD
University of Illinois Chicago
Victor Gordeuk, MD
University of Illinois Chicago
Richard Penn, MD
University of Illinois Chicago
William Mieler, MD
University of Illinois Chicago
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”